pateclizumab

Home
Ligands
pateclizumab

GtoPdb Ligand ID: 9854

Synonyms: MLTA3698A | PRO283698 | RG7416

Comment: Pateclizumab is a humanized anti-lymphotoxin alpha (LTA) monoclonal antibody that is being investigated for anti-inflammatory potential. Peptide sequences for the heavy and light chains of pateclizumab are 100% matches to sequences 106 and 107 that are claimed in Genentech's patent US7923011B2 [1]. Sequences 106 and 107 identify pateclizumab as antibody 2C8.vX as defined in the patent.

No information available.

No information available.

Summary of Clinical Use
Pateclizumab (as research code MLTA3698A) has completed Phase 2 clinical trial in patients with active rheumatoid arthritis. In this trial (NCT01225393) MLTA3698A plus a DMARD was directly compared with adalimumab plus a DMARD, and results were reported by Kennedy et al. (2014) [4].

Summary of Clinical Use

Pateclizumab (as research code MLTA3698A) has completed Phase 2 clinical trial in patients with active rheumatoid arthritis. In this trial (NCT01225393) MLTA3698A plus a DMARD was directly compared with adalimumab plus a DMARD, and results were reported by Kennedy et al. (2014) [4].

Mechanism Of Action and Pharmacodynamic Effects
The role of LTA in RA is reviewed by Hirose et al. (2018) [3].

Mechanism Of Action and Pharmacodynamic Effects

The role of LTA in RA is reviewed by Hirose et al. (2018) [3].

Clinical Trials
Clinical Trial ID	Title	Type	Source	Comment	References
NCT01225393	A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis	Phase 2 Interventional	Genentech, Inc.